PL1784161T3 - Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny - Google Patents

Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny

Info

Publication number
PL1784161T3
PL1784161T3 PL05774341T PL05774341T PL1784161T3 PL 1784161 T3 PL1784161 T3 PL 1784161T3 PL 05774341 T PL05774341 T PL 05774341T PL 05774341 T PL05774341 T PL 05774341T PL 1784161 T3 PL1784161 T3 PL 1784161T3
Authority
PL
Poland
Prior art keywords
dissolution
tamsulosin hydrochloride
buffer
controlled
hours
Prior art date
Application number
PL05774341T
Other languages
English (en)
Inventor
Lech Wiąckowski
Wiesław Szelejewski
Andrzej Zaremba
Edyta Pesta-Dynda
Zofia Marchlewska-Cela
Original Assignee
Inst Farmaceutyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Farmaceutyczny filed Critical Inst Farmaceutyczny
Publication of PL1784161T3 publication Critical patent/PL1784161T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05774341T 2004-08-12 2005-08-12 Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny PL1784161T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
PCT/PL2005/000052 WO2006016829A1 (en) 2004-08-12 2005-08-12 Controlled-release formulation comprising tamsulosin hydrochloride
EP05774341A EP1784161B1 (en) 2004-08-12 2005-08-12 Controlled-release formulation comprising tamsulosin hydrochloride

Publications (1)

Publication Number Publication Date
PL1784161T3 true PL1784161T3 (pl) 2008-05-30

Family

ID=35445840

Family Applications (2)

Application Number Title Priority Date Filing Date
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
PL05774341T PL1784161T3 (pl) 2004-08-12 2005-08-12 Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania

Country Status (7)

Country Link
US (1) US20070298101A1 (pl)
EP (1) EP1784161B1 (pl)
AT (1) ATE382332T1 (pl)
DE (1) DE602005004164T2 (pl)
PL (2) PL204079B1 (pl)
SI (1) SI1784161T1 (pl)
WO (1) WO2006016829A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
JP2015500241A (ja) * 2011-12-02 2015-01-05 ペガサス ラボラトリーズ インコーポレイテッド 両親媒性脂質をベースとする徐放性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
JP4019374B2 (ja) * 2001-07-27 2007-12-12 アステラス製薬株式会社 口腔内速崩壊錠用徐放性微粒子含有組成物およびその製造法
JP2005512997A (ja) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠

Also Published As

Publication number Publication date
WO2006016829A1 (en) 2006-02-16
EP1784161B1 (en) 2008-01-02
DE602005004164D1 (de) 2008-02-14
ATE382332T1 (de) 2008-01-15
PL204079B1 (pl) 2009-12-31
US20070298101A1 (en) 2007-12-27
DE602005004164T2 (de) 2008-12-11
SI1784161T1 (sl) 2008-06-30
EP1784161A1 (en) 2007-05-16
PL369566A1 (pl) 2006-02-20

Similar Documents

Publication Publication Date Title
Kranz et al. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug
US6333332B1 (en) Stabilized pharmaceutical compositions containing bupropion hydrochloride
AU2013344281B2 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
US10258584B2 (en) Pregabalin sustained-release preparation
JP2009538918A (ja) フェニレフリンを含有する徐放薬学的投薬形態
US9393205B2 (en) Gastroretentive tablets
EP2352494A1 (en) Novel and potent tapentadol dosage forms
MX2012013135A (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
TW201334780A (zh) 多西拉敏及吡哆醇及／或其代謝物或鹽之調配物
US20240139109A1 (en) Pharmaceutical formulations
US9907789B2 (en) Sustained-release preparation
EP2902016A1 (en) Febuxostat tablet
Kranz et al. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug
US20080138411A1 (en) Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors
US20060182797A1 (en) Sutained release formulation for venlafaxine hydrochloride
US20100003322A1 (en) Enteric coated hydrophobic matrix formulation
KR101464053B1 (ko) 4-메틸피라졸 배합물
UA75831C2 (en) Process for preparation of tablets from pharmaceutically active ingredients having unfavourable tabletting properties with the use of granulating liquid containing microcrystalline cellulose
SI1784161T1 (sl) Formulacija s kontroliranim sproščanjem, ki vsebuje tamsulosin hidroklorid
US20150148388A1 (en) Chemical composition
EP3067042A1 (en) Floating system for the treatment of gastric disorders
UA87513C2 (ru) Фармацевтическая композиция, содержащая дроспиренон и этинилэстрадиол
Avachat et al. Effect of alcohol on drug release kinetics from HPMC-based matrix tablets using model drugs
CN105492013A (zh) 用于管理恶心和呕吐的组合物
EP1628642B1 (en) Controlled drug release composition resistant to in vivo mechanic stress